Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917553 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL917254 | 0.87 | GALR3 (0.61) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL917252 | 0.87 | GALR3 (0.61) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL916613 | 0.85 | KDM4E (0.55) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL916611 | 0.85 | KDM4E (0.55) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL8091722 | 0.85 | ALDH1A1 (0.53) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL916909 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL916908 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL918013 | 0.81 | GALR3 (0.63) | ALDH1A1KDM4EPKMCA12CA2 | |
| SCHEMBL918014 | 0.81 | GALR3 (0.63) | ALDH1A1KDM4EPKMCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| EP-2241316-A1 | Indolone compounds useful to treat cognitive impairment | Helicon Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2004-05-27 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014307-A2 | GAL3 ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | ALDH1A1 1921/4885KDM4E 4396/4885PKM 1909/4885 |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | ALDH1A1 2577/4885KDM4E 4009/4885PKM 2045/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | ALDH1A1 1194/4885KDM4E 4371/4885PKM 3339/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | ALDH1A1 3303/4885KDM4E 4395/4885PKM 3138/4885 |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | ALDH1A1 2577/4885KDM4E 4009/4885PKM 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.